In November, RheumPAC will be leading its annual matching campaign and hosting two events at ACR Convergence 2022. Thanks to matching donors, every contribution in November will be amplified.

Subcategories:Clinical Criteria/GuidelinesEthicsLegal UpdatesLegislation & AdvocacyMeeting ReportsResearch Rheum
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
In November, RheumPAC will be leading its annual matching campaign and hosting two events at ACR Convergence 2022. Thanks to matching donors, every contribution in November will be amplified.
Elizabeth "Blair" Solow, MD |
Outgoing Government Affairs Committee Chair Blair Solow, MD, offers advocacy updates from 2022 and seasonal reflections on how to stay focused on efforts that matter when faced with daunting challenges.
This session at ACR Convergence 2022, on Monday, Nov. 14, 2022, from 9–10 a.m. EST, will examine guidelines and current evidence regarding the management and outcomes of patients with ankylosing spondylitis (AS). Alexis Ogdie, MD, a rheumatologist and associate professor of Medicine at the University of Pennsylvania, Philadelphia, will present data to highlight the evolution…
A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.
Emily A. Johnson, JD |
Healthcare businesses are a hot commodity in the market today. A buyer may even be interested in your healthcare practice right now. Whether or not you’ve gone down the road of selling your practice before, the process can be stressful and time consuming. A lot of the time and stress centers around one aspect of…
Daniel K. White, PT, ScD, MSc, & Susan Bartlett, PhD |
High-quality mentoring is perhaps the most recognized ingredient to a successful career, one that remains little understood. Here, we present a brief overview of the elements of successful mentor-mentee relationships for clinicians and scientists in rheumatology. We discuss the importance of mentorship and characteristics of good mentoring, and offer our personal reflections as both mentees…
With ~60 research abstracts on gout accepted for presentation at ACR Convergence 2022, filtering the noise to get to the key thoughts may be challenging. Lisa Stamp, MBChB, PhD, can help. A rheumatologist, professor of medicine and the associate dean of research at the University of Otago in Christchurch, New Zealand, she has extensively researched…
On Monday, Nov. 14, Michael Pillinger, MD, will moderate the session Gout Is an Autoinflammatory Metabolic Disease at ACR Convergence 2022. This session will address the autoinflammatory nature of gout and highlight it as an IL-1β-mediated diseases. Increasing knowledge on the inflammatory mechanisms of gout has implications for disease management. These engaging talks will review…
WASHINGTON, D.C.—On Sept. 14, the ACR praised the House of Representatives for overwhelmingly passing bipartisan legislation intended to make it easier for Medicare Advantage beneficiaries to access the timely care they need. The Improving Seniors’ Timely Access to Care Act (H.R. 3173) passed the House on a voice vote. If enacted, the bill will create…
ATLANTA—The ACR released a summary of its updated guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in September. Many patients take glucocorticoids for a variety of inflammatory conditions, and anyone who is taking glucocorticoid medications and has other risk factors for osteoporosis increases their risk of developing glucocorticoid-induced osteoporosis. New osteoporosis medications and new…